Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AssigneeNovartis AG
InventorsJames Douglas GRIFFIN, Paul William MANLEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Claims15
A method for treating a mammal suffering from a disease involving deregulated FLT3 receptor tyrosine kinase activity comprising administering to a mammal in need of such treatment a therapeutically effective amount of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide of the formula (VII):
- or a salt thereof.
Dependencies are inferred from the claim text.